ENDRA Life Sciences NDRA recently announced positive findings from a clinical study assessing the measurement consistency of ...

ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, ...

WASHINGTON & OXFORD, England--(BUSINESS WIRE)--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis ...

ENDRA Life Sciences has reported results from a clinical study showing the Taeus Liver device’s high measurement consistency ...

Quibim, a global company pioneering imaging biomarkers for precision medicine, is today announcing the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver diseases through ...

New findings from the DIRECT PLUS, 18-month-long lifestyle intervention trial underscores the potential to observe and signify alterations of MRI-assessed liver fat with proteomics according to new ...

Never-before-seen 3D reconstructions of human liver tissue have been created at a cellular level. The details obtained by a ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc ...